C5AR1
Reaktivität: Human
WB, PLA
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1.0 mg/mL
Baelder, Fuchs, Bautsch, Zwirner, Köhl, Hoymann, Glaab, Erpenbeck, Krug, Braun: "Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 174, Issue 2, pp. 783-9, (2005) (PubMed).
Godau, Heller, Hawlisch, Trappe, Howells, Best, Zwirner, Verbeek, Hogarth, Gerard, Van Rooijen, Klos, Gessner, Köhl: "C5a initiates the inflammatory cascade in immune complex peritonitis." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 173, Issue 5, pp. 3437-45, (2004) (PubMed).
Soruri, Kim, Kiafard, Zwirner: "Characterization of C5aR expression on murine myeloid and lymphoid cells by the use of a novel monoclonal antibody." in: Immunology letters, Vol. 88, Issue 1, pp. 47-52, (2003) (PubMed).